Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo

Rociletinib (CO-1686) enhanced the efficacy of chemotherapeutic agents in ABCG2-overexpressing cancer cells in vitro and in vivo

Overexpression of adenosine triphosphate (ATP)-binding cassette subfamily G member 2 (ABCG2) in cancer cells is known to cause multidrug resistance (MDR), which severely limits the clinical efficacy of chemotherapy. Currently, there is no FDA-approved MDR modulator for clinical use. In this study, r...

Full description

Bibliographic Details
Main Authors: Fanpu Zeng, Fang Wang, Zongheng Zheng, Zhen Chen, Kenneth Kin Wah To, Hong Zhang, Qian Han, Liwu Fu
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:Acta Pharmaceutica Sinica B
Subjects:
Rociletinib
Tyrosine kinase inhibitor
Multidrug resistance
ABCG2
ATPase
Online Access:http://www.sciencedirect.com/science/article/pii/S2211383519310743

Similar Items

Similar Items